Last reviewed · How we verify
Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery
Approved treatments
- Fragmin · Pfizer Inc.
Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery patent landscape — cliff calendar, originator estates, attackable patents
- Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery treatment landscape brief
- Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery treatment updates RSS
Frequently asked questions about Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery
What drugs treat Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery?
Tracked treatments include Fragmin.
What is the treatment for Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery?
Standard treatment for Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery includes Fragmin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery patent cliff · Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery CI report
- Treatment: Fragmin · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing